Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone for Ovulation in Girls with Androgen Excess
NCT04075149Phase 1Unknown
- Sponsor
- University of Virginia
- Start
- Dec 2019
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of spironolactone in Hyperandrogenism, sponsored by University of Virginia. Primary endpoint: Ovulation Rate Changes. Status: unknown.
02
Drugs
spironolactone
03
Conditions
Hyperandrogenism
Beyond the preview
Go deeper on NCT04075149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04075149.